Redx Pharma plc Development candidate chosen for leukaemia program (9968M)
October 20 2016 - 1:00AM
UK Regulatory
TIDMREDX
RNS Number : 9968M
Redx Pharma plc
20 October 2016
AIM: REDX
REDX PHARMA PLC
("Redx" or "the Company" or "the Group")
Development candidate chosen for leukaemia program
Redx, the drug development company, is pleased to announce that
it has identified a drug development candidate for its reversible
Bruton's tyrosine kinase ("BTK") inhibitor program. The compound,
named RXC005, has the potential to treat the majority of patients
suffering from chronic lymphocytic leukaemia ("CLL"), including
those who become resistant to the increasingly used treatment
ibrutinib.
RXC005 is equally potent against the most common type of BTK
protein implicated in CLL and the mutant BTK protein, which is
currently estimated to be responsible for around 60% of the
observed ibrutinib resistance. Redx's BTK inhibitor could also
offer a reduced side-effect profile compared to ibrutinib.
The Company will now progress studies to prepare the RXC005
program for first-in-human clinical trials. These trials are
currently expected to commence in early 2018.
Dr Neil Murray, CEO of Redx, said:
"We're delighted to announce another cancer drug candidate from
our innovative development pipeline. The nomination of RXC005, a
novel reversible BTK inhibitor, comes within a month of confirming
the planned start of clinical trials for our most advanced program,
the Porcupine inhibitor, in some hard-to-treat cancers.
"RXC005 has the potential to become a potent therapy for chronic
lymphocytic leukaemia patients, including those resistant to
ibrutinib treatment. We plan to initiate first-in-human studies for
RXC005 early 2018."
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulations (EU) No. 596/2014. Upon the publication of this
announcement, this inside information is now considered to be in
the public domain.
For further information, please contact:
Redx Pharma Plc
Neil Murray, Chief Executive T: +44 151
706 4747
Karl Hård, Head of Investor T: +44 7491
Relations & 651 406
Corporate Communications
Cantor Fitzgerald Europe (Nomad T: +44 20
& Broker) 7894 7000
Phil Davies/ Michael Reynolds
KTZ Communications T: +44 20
3178 6378
Katie Tzouliadis/ Viktoria Langley/
Emma Pearson
About Redx Pharma Plc
Company website: Redxpharma.com
Redx is focused on the discovery and development of proprietary,
small molecule therapeutics to address areas of high, unmet medical
need, principally in cancer, infection and immunology, providing a
pipeline of assets to larger and emerging companies. By improving
the characteristics of existing drug classes to create highly
differentiated, novel, best-in-class drugs, Redx has already
established a portfolio of 14 proprietary drug programs. Seven
proof of concepts have been achieved across five programs, with
relevance for respective therapies to treat MRSA, gonorrhoea, bone
tumours, skin, brain, breast, pancreatic and blood cancers.
About Chronic Lymphocytic Leukaemia ("CLL")
CLL is one of the most common types of leukaemia in adults. In
the US, it is estimated that there will be approximately 19,000
cases of CLL diagnosed in 2016. Around 3,400 new cases of chronic
lymphocytic leukaemia were diagnosed in the UK in 2013.
CLL occurs where the body produces abnormal levels of white
blood cells - specifically B cells. As the disease progresses, the
B cells crowd out healthy cells in the blood and bone marrow
leaving the body unable to fight infection.
Additional sources:
National Cancer Institute (US) -
http://www.cancer.gov/types/leukemia/research/ibrutinib-cll
Cancer Research UK -
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cll#heading-Zero
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulations (EU) No. 596/2014. Upon the publication of this
announcement, this inside information is now considered to be in
the public domain.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDKLFFQBFLFBZ
(END) Dow Jones Newswires
October 20, 2016 02:00 ET (06:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024